Effect of anamorelin on body weight in patients with gastric cancer-associated cachexia: an observational study
Open Access
- 8 July 2025
- journal article
- research article
- Published by Springer Nature in Gastric Cancer
- Vol. 28 (5) , 945-954
Abstract
Background: In 2021, anamorelin, a ghrelin receptor agonist, was approved in Japan for cancer cachexia in select cancers, including gastric cancer. However, evidence regarding its efficacy and predictive factors in patients with gastric cancer remains lacking. Methods: This prospective observational study encompassed 229 patients with unresectable, advanced, or recurrent gastric cancer and cancer cachexia who received anamorelin from 2021 to 2023 at 25 institutions affiliated with Osaka University. Body weight change at 12 weeks was the primary endpoint. Appetite, food intake, treatment compliance, and adverse events comprised the secondary endpoints. Multivariable logistic regression analyses were employed for identifying weight gain predictors. Results: Of the 229 patients (median age, 73 years), 126 completed the 12-week follow-up. The median anamorelin administration duration was 62 days. The mean weight significantly increased from baseline to 4, 8, and 12 weeks (up to + 0.88 kg, p < 0.001). Moreover, appetite and food intake improved. Multivariable analysis identified baseline body mass index (BMI) < 20 kg/m 2 and neutrophil-to-lymphocyte ratio (NLR) < 4.0 as independent predictors of significant weight gain at 12 weeks. Treatment was generally well tolerated, with a 41% completion rate; 59% of the participants discontinued mainly owing to disease progression. Conclusion: In patients with gastric cancer-related cachexia, anamorelin was associated with significant increases in body weight and improvements in appetite. Lower BMI and lower systemic inflammation (NLR < 4.0) were predictive of better response.Keywords
Funding Information
- Japanese Gastric Cancer Association (JGCA-031)
- The University of Osaka
This publication has 22 references indexed in Scilit:
- Anamorelin Efficacy in Non–Small‐Cell Lung Cancer Patients With Cachexia: Insights From ROMANA 1 and ROMANA 2Journal of Cachexia, Sarcopenia and Muscle, 2025
- Real‐world safety and effectiveness of anamorelin for cancer cachexia: Interim analysis of post‐marketing surveillance in JapanCancer Medicine, 2024
- Systemic inflammation adversely affects response to anamorelin in patients with pancreatic cancerSupportive Care in Cancer, 2023
- Usefulness of the cachexia index as a prognostic indicator for patients with gastric cancerAnnals of Gastroenterological Surgery, 2023
- Clinical impact of perirenal thickness on short‐ and long‐term outcomes of gastric cancer after curative surgeryAnnals of Gastroenterological Surgery, 2022
- Oral nutritional supplements versus a regular diet alone for body weight loss after gastrectomy: a phase 3, multicenter, open-label randomized controlled trialGastric Cancer, 2021
- A multicenter, open‐label, single‐arm study of anamorelin (ONO‐7643) in advanced gastrointestinal cancer patients with cancer cachexiaCancer, 2019
- Cachexia and sarcopenia: mechanisms and potential targets for interventionCurrent Opinion in Pharmacology, 2015
- The systemic inflammation-based Glasgow Prognostic Score: A decade of experience in patients with cancerCancer Treatment Reviews, 2013
- High preoperative neutrophil-lymphocyte ratio predicts poor survival in patients with gastric cancerGastric Cancer, 2010